Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProF-001 (Diclofenac + Clotrimazole) in Vulvovaginal Candidiasis
NCT03115073Phase 3Completed
- Sponsor
- ProFem
- Start
- Apr 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of diclofenac in vulvovaginal candidiasis (VVC) (4 arms), sponsored by ProFem. Primary endpoint: Combined outcome measure of: Symptom relief within the first 60 minutes and clinical cure at day 7. Started Apr 2017; status: completed.
02
Drugs
diclofenac
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on NCT03115073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03115073.